Peptides DB
Research-centric peptide and protocol reference hub
Study 46 of 48Vasopressin literaturebiorxiv-preprint · Observational2026

Cost Analysis of Vasopressin Use in Septic Shock and Predictive Performance of GOSSIS in ICU Mortality

Vasopressin use in septic shock is associated with a 14% increase in hospitalization costs compared to alternative vasopressors, highlighting the need for careful cost consideration in critical care.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the vasopressin corpus
9
Preclinical
35
Observational · this one
1
Open-label
2
Randomised
1
Reviews

Summary and findings

This study evaluated healthcare costs associated with vasopressin use in septic shock and assessed the predictive performance of the Global Open-Source Severity of Illness Score (GOSSIS). A total of 3,898 adult ICU patients were analyzed, with 1,060 receiving vasopressin. The study found a 14% increase in hospitalization costs for vasopressin users compared to those using alternative vasopressors.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
cost ratio = 1.14, 95% CI: 1.08, 1.202026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>Background: </h4> Vasopressin is a commonly used adjunctive therapy in the management of septic shock. While vasopressin may provide clinical benefits, at times its acquisition cost has risen to being substantially more expensive than other second-line vasopressors such as epinephrine, phenylephrine, or dopamine. Additionally, mortality prediction tools such as the Global Open-Source Severity of Illness Score (GOSSIS) have emerged as a valuable resource to guide resource allocation in critical care. This study aimed to evaluate the healthcare costs associated with vasopressin use and assess the predictive performance of GOSSIS in patients with septic shock. <h4>Methods:</h4> We conducted a multi-center retrospective cohort study of adult ICU patients with septic shock treated throughout the UPMC Health System from January 2021 to January 2022. Patients who received norepinephrine as a first-line vasopressor followed by either vasopressin or an alternative vasopressor were included. Generalized linear models with a log link and gamma distribution were used to compare adjusted total healthcare costs. Recycled predictions were used to estimate marginal cost differences. GOSSIS performance was evaluated by comparing predicted versus observed ICU mortality across risk groups. <h4>Results:</h4> Among 3,898 eligible patients, 1,060 received vasopressin and 2,838 received alternative second-line vasopressors. Vasopressin use was associated with significantly higher adjusted hospital costs (cost ratio = 1.14, 95% CI: 1.08, 1.20). The estimated marginal cost difference was $5,887 per patient. Drug costs accounted for a greater proportion of total hospitalization costs among vasopressin users (20% vs. 12%). GOSSIS demonstrated strong calibration, with predicted ICU mortality closely aligning with observed rates across all severity strata. <h4>Conclusions:</h4> Vasopressin use in septic shock was associated with a 14% increase in hospitalization costs compared to alternative second-line vasopressors. The GOSSIS demonstrated strong predictive validity for ICU mortality, supporting its potential use in guiding resource allocation decisions in critically ill populations.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Vasopressin corpus

BRefractory circulatory shock following intentional polypharmacy antihypertensive and NSAID overdose: Clinical recovery temporally associated with sequential intravenous lipid emulsion and methylene blue - A case report.Toxicology reports · 2026 · n=1 · Lactate fell from 10.5 to 6.1 mmol/L over 55 min.HumanCAllelic heterogeneity and cystic pathway modulation in HNF1B diseasebiorxiv-preprint · 2026 · Not reported in abstract.AnimalCAVPR2 antagonism with tolvaptan alters medullary cell responses and attenuates kidney injurybiorxiv-preprint · 2026 · Not reported in abstract.AnimalBFluid Resuscitation Volume After Early Echocardiography and Mortality in Sepsis: Target Trial Emulations With Strictly Pre-Exposure Confounder Measurement in MIMIC-IVbiorxiv-preprint · 2023 · n=7819 · HR 1.74, 95% CI 1.54–1.97; weighted risk 38.7% vs 24.8%; risk difference +13.9%, 95% CI 10.8–17.0.HumanBAcute colonic pseudo-obstruction with transient failure of oral desmopressin in adipsic arginine vasopressin deficiency.JCEM case reports · 2023 · n=1 · Not reported in abstract.HumanAEffect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial.JAMA · 2026 · Mortality at 28 days was 31.8% in the lower-threshold group vs 33.0% in the higher-threshold group, P=0.62.Human